We serve N,N-dimethyl-3-oxobutanamide CAS:2044-64-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Items of Analysis | Standard of Analysis | Test Results |
Appearance | Yellow clear liquid | Conform |
pH | 6.0-8.0 | 6.31 |
Dimethyl acetoacetamide | ≥79.0% | 79.19% |
Color value | ≤350 APHA | 245 APHA |
Conclusion | Conforms to Factory Standard |
Contact us for information like N,N-dimethyl-3-oxobutanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Butanamide,N,N-dimethyl-3-oxo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 218-059-8 Use and application,N,N-dimethyl 3-oxobutanamide technical grade,usp/ep/jp grade.
Related News: “We believe such actions are our last resort,” the Hospital Authority Employees Alliance, a union that formed during the city’s antigovernment protest movement, wrote in a statement.9H-Carbazole-3-carbonitrile, 8-fluoro-1,4-dimethyl- manufacturer “We believe such actions are our last resort,” the Hospital Authority Employees Alliance, a union that formed during the city’s antigovernment protest movement, wrote in a statement.6β-[6β-(2,6-dimethoxy-benzoylamino)-penicillanoylamino]-penicillanic acid benzyl ester supplier Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.2-((23-trioxidaneyl)oxy)-2-(1-oxidaneyl)-2H-24,33,43-hexaoxine hydrate vendor Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.